Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment

K. Mimori, N. Sadanaga, Y. Yoshikawa, K. Ishikawa, M. Hashimoto, F. Tanaka, A. Sasaki, H. Inoue, K. Sugimachi, M. Mori

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

A recent study disclosed that breast cancer cases with low 'tau' expression can predict susceptibility to Paclitaxel administration. In the current study, the clinical significance of tau expression in gastric cancer cases was established by identifying candidates with Paclitaxel administration. Tissue specimens from 20 cases of in-operable or noncuratively resected gastric cancer were examined. Subsequent to the administration of 80 mg m-2 of Paclitaxel in six 3-h intravenous infusions, the clinical effectiveness of Paclitaxel was evaluated by the size of metastatic lesions with computed tomography. The status of the tau expression was determined by immunohistochemistry. Based on a previously reported classification scheme, six were classified as tau-negative expression (0, 1+) cases and 14 were classified as tau-positive expression (2+, 3+) cases. All six (100%) cases of tau-negative expression showed a favourable response (partial response or minor response) to Paclitaxel administration. However, 12 (86%) of the 14 cases of tau-positive expression showed progressive disease (n=11) or no change (n=1) after Paclitaxel administration. The serum carcinoembryonic antigen values of the six cases of tau-negative expression were markedly decreased in comparison to the 14 tau-positive cases. These data indicate that tau-negative expression can be used to select gastric cancer patients, which will favourably respond to Paclitaxel treatment.

Original languageEnglish
Pages (from-to)1894-1897
Number of pages4
JournalBritish journal of cancer
Volume94
Issue number12
DOIs
Publication statusPublished - Jun 19 2006

Fingerprint

Paclitaxel
Stomach Neoplasms
Therapeutics
Carcinoembryonic Antigen
Intravenous Infusions
Immunohistochemistry
Tomography
Breast Neoplasms
Serum

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment. / Mimori, K.; Sadanaga, N.; Yoshikawa, Y.; Ishikawa, K.; Hashimoto, M.; Tanaka, F.; Sasaki, A.; Inoue, H.; Sugimachi, K.; Mori, M.

In: British journal of cancer, Vol. 94, No. 12, 19.06.2006, p. 1894-1897.

Research output: Contribution to journalArticle

Mimori, K, Sadanaga, N, Yoshikawa, Y, Ishikawa, K, Hashimoto, M, Tanaka, F, Sasaki, A, Inoue, H, Sugimachi, K & Mori, M 2006, 'Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment', British journal of cancer, vol. 94, no. 12, pp. 1894-1897. https://doi.org/10.1038/sj.bjc.6603182
Mimori, K. ; Sadanaga, N. ; Yoshikawa, Y. ; Ishikawa, K. ; Hashimoto, M. ; Tanaka, F. ; Sasaki, A. ; Inoue, H. ; Sugimachi, K. ; Mori, M. / Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment. In: British journal of cancer. 2006 ; Vol. 94, No. 12. pp. 1894-1897.
@article{f059cce4786a4c19bf2ce7917838e9dc,
title = "Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment",
abstract = "A recent study disclosed that breast cancer cases with low 'tau' expression can predict susceptibility to Paclitaxel administration. In the current study, the clinical significance of tau expression in gastric cancer cases was established by identifying candidates with Paclitaxel administration. Tissue specimens from 20 cases of in-operable or noncuratively resected gastric cancer were examined. Subsequent to the administration of 80 mg m-2 of Paclitaxel in six 3-h intravenous infusions, the clinical effectiveness of Paclitaxel was evaluated by the size of metastatic lesions with computed tomography. The status of the tau expression was determined by immunohistochemistry. Based on a previously reported classification scheme, six were classified as tau-negative expression (0, 1+) cases and 14 were classified as tau-positive expression (2+, 3+) cases. All six (100{\%}) cases of tau-negative expression showed a favourable response (partial response or minor response) to Paclitaxel administration. However, 12 (86{\%}) of the 14 cases of tau-positive expression showed progressive disease (n=11) or no change (n=1) after Paclitaxel administration. The serum carcinoembryonic antigen values of the six cases of tau-negative expression were markedly decreased in comparison to the 14 tau-positive cases. These data indicate that tau-negative expression can be used to select gastric cancer patients, which will favourably respond to Paclitaxel treatment.",
author = "K. Mimori and N. Sadanaga and Y. Yoshikawa and K. Ishikawa and M. Hashimoto and F. Tanaka and A. Sasaki and H. Inoue and K. Sugimachi and M. Mori",
year = "2006",
month = "6",
day = "19",
doi = "10.1038/sj.bjc.6603182",
language = "English",
volume = "94",
pages = "1894--1897",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment

AU - Mimori, K.

AU - Sadanaga, N.

AU - Yoshikawa, Y.

AU - Ishikawa, K.

AU - Hashimoto, M.

AU - Tanaka, F.

AU - Sasaki, A.

AU - Inoue, H.

AU - Sugimachi, K.

AU - Mori, M.

PY - 2006/6/19

Y1 - 2006/6/19

N2 - A recent study disclosed that breast cancer cases with low 'tau' expression can predict susceptibility to Paclitaxel administration. In the current study, the clinical significance of tau expression in gastric cancer cases was established by identifying candidates with Paclitaxel administration. Tissue specimens from 20 cases of in-operable or noncuratively resected gastric cancer were examined. Subsequent to the administration of 80 mg m-2 of Paclitaxel in six 3-h intravenous infusions, the clinical effectiveness of Paclitaxel was evaluated by the size of metastatic lesions with computed tomography. The status of the tau expression was determined by immunohistochemistry. Based on a previously reported classification scheme, six were classified as tau-negative expression (0, 1+) cases and 14 were classified as tau-positive expression (2+, 3+) cases. All six (100%) cases of tau-negative expression showed a favourable response (partial response or minor response) to Paclitaxel administration. However, 12 (86%) of the 14 cases of tau-positive expression showed progressive disease (n=11) or no change (n=1) after Paclitaxel administration. The serum carcinoembryonic antigen values of the six cases of tau-negative expression were markedly decreased in comparison to the 14 tau-positive cases. These data indicate that tau-negative expression can be used to select gastric cancer patients, which will favourably respond to Paclitaxel treatment.

AB - A recent study disclosed that breast cancer cases with low 'tau' expression can predict susceptibility to Paclitaxel administration. In the current study, the clinical significance of tau expression in gastric cancer cases was established by identifying candidates with Paclitaxel administration. Tissue specimens from 20 cases of in-operable or noncuratively resected gastric cancer were examined. Subsequent to the administration of 80 mg m-2 of Paclitaxel in six 3-h intravenous infusions, the clinical effectiveness of Paclitaxel was evaluated by the size of metastatic lesions with computed tomography. The status of the tau expression was determined by immunohistochemistry. Based on a previously reported classification scheme, six were classified as tau-negative expression (0, 1+) cases and 14 were classified as tau-positive expression (2+, 3+) cases. All six (100%) cases of tau-negative expression showed a favourable response (partial response or minor response) to Paclitaxel administration. However, 12 (86%) of the 14 cases of tau-positive expression showed progressive disease (n=11) or no change (n=1) after Paclitaxel administration. The serum carcinoembryonic antigen values of the six cases of tau-negative expression were markedly decreased in comparison to the 14 tau-positive cases. These data indicate that tau-negative expression can be used to select gastric cancer patients, which will favourably respond to Paclitaxel treatment.

UR - http://www.scopus.com/inward/record.url?scp=33745063686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745063686&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6603182

DO - 10.1038/sj.bjc.6603182

M3 - Article

C2 - 16721363

AN - SCOPUS:33745063686

VL - 94

SP - 1894

EP - 1897

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 12

ER -